Scarlet Raises $50M—AI Certification Expands to the US and APAC

London-based Scarlet raised a $50 million Series B on October 12, 2026, led by Headline. The investor list reported by Axios includes new backer Notion Capital and returning investors Atomico, Creandum, Kindred Capital and Entrepreneurs First. Scarlet assesses software and AI medical devices for manufacturers seeking to bring regulated products to market.

In its funding announcement, Scarlet says it will grow its expert team, broaden its certification work and increase its presence in the US and Asia-Pacific; it also says customers have cut a year or more from initial certification timelines and shortened product-update cycles from months to weeks. Those time savings are company-reported customer outcomes, not a published measure of Scarlet’s typical review time or overall capacity.

Funding expert review as well as software

Scarlet’s expansion requires people qualified to make regulatory judgments. In Headline’s account of the investment, co-founder James Dewar says Scarlet will “build out our global presence,” while the investor describes technology that organises manufacturers’ documentation for qualified reviewers. That division of work is central to the business: a more orderly submission can reduce time spent handling evidence, but a specialist still has to assess what the evidence shows.

For a certification body, growth is therefore partly a staffing problem. More manufacturers and more product changes can mean more technical files, questions and decisions for reviewers. Software may help specialists find and track the relevant material, while additional hires can increase the number of cases Scarlet is equipped to handle. Neither change alone establishes how many assessments the expanded team will complete or how long a manufacturer will wait. The time also depends on the device, the evidence supplied and any issues raised during review.

Scarlet’s European authority has a defined scope

The European Commission’s notification for Scarlet NB B.V. lists it as notified body NB 3022 under the EU Medical Device Regulation, with software in its scope and procedures covering quality-management systems and technical documentation. A notified body is designated to carry out specified assessments of manufacturers and devices. The listing establishes which European work Scarlet is authorised to perform; it is not a performance record for the speed of that work.

That distinction matters when Scarlet describes international growth. A manufacturer needs an assessment route that applies to its device and the market where it intends to sell it. An EU notified-body designation has a defined European regulatory role; increasing Scarlet’s presence in the US or Asia-Pacific does not extend that designation across those jurisdictions. The round provides capital for an overseas push, while the services Scarlet offers in each market depend on the rules and authorisations that apply there.

Frequent software changes keep assessment work coming

Medical software can change after its first release. A revised model, feature or intended use may call for updated technical evidence and, depending on the change and regulatory route, further assessment before the revised device reaches patients. Manufacturers must be able to explain what changed and why the product remains safe and effective. For a certifier, that creates work beyond an initial decision: successive releases can bring new documentation and questions about the basis for approval.

The resulting delay can arise at more than one point. A submission may need clearer evidence before a reviewer can assess it; a qualified reviewer may have a queue; and a technical finding may require the manufacturer to respond. Organising documents more efficiently addresses the first part of that process. Hiring specialists addresses review capacity. Scarlet’s proposed combination explains why investors would fund both software-supported workflow and an expert team, and why faster document intake should not be treated as the same thing as a faster certification decision.

Customer speed claims await a broader record

The reported reduction of a year or more for new devices and the shift from months to weeks for updates describe outcomes Scarlet attributes to its customers. They give a concrete account of the benefit the company is selling, but they do not establish a typical result. Case complexity, the starting point used to measure elapsed time and the kinds of changes included in an update cycle can all affect the comparison. The announcement gives no comparable series of completed cases from which to calculate a company-wide review time.

As Scarlet adds specialists and pursues new markets, the measure of that investment will be completed assessments at a dependable pace, with decisions grounded in adequate evidence. Figures that distinguish initial certifications from later changes, and identify the jurisdictions and device types involved, would make its claimed acceleration easier to judge. For manufacturers planning a launch, the immediate consequence is more funding behind a specialist certifier; the effect of that expansion on waiting times remains to be demonstrated.

Also read:

• Nettle Raises $4.8M—Its Fivefold Speed Claim Is Still Vendor-Reported
• Gallatin Raises $50M—Military Logistics Still Starts With Clipboards
• Hadrian Raises $40M—Offensive AI Becomes a Funding Category